EUVIMEDEUVIMED entdecken
Open Access

MC16 promotes mitochondrial biogenesis and ameliorates acute and diabetic nephropathy

Austin D Thompson iD, Kevin A Hurtado iD, Jaroslav Janda, Natalie E Scholpa iD, Baerbel Rohrer, Rick G Schnellmann

British Journal of Pharmacology · 2025

DOI: 10.1111/bph.17440 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Pharmacology, 2025. Verfasst von Austin D Thompson und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Toxicology, College of Pharmacy, University of Arizona, Tucson, Arizona, USA. Hauptthemen laut MEDLINE: Organelle Biogenesis, Diabetic Nephropathies, Acute Kidney Injury, Mitochondria. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 76 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: U.S. Department of Veterans Affairs, NIEHS NIH HHS, BLRD VA.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Purpose Kidney disease (KD) is a leading cause of mortality worldwide, affecting 〉10% of the global population. Two of the most common causes of KD are diabetes and acute kidney injury (AKI), both of which induce mitochondrial dysfunction resulting in renal proximal tubular damage/necrosis. Thus, pharmacological induction of mitochondrial biogenesis (MB) may provide a therapeutic strategy to block the onset/progression of KD. Here, we evaluated the pharmacological and potential therapeutic effects of a novel MB‐inducing oxindole agent, MC16 . Experimental Approach Primary cultures of rabbit renal proximal tubule cells (RPTCs) were used to evaluate the cellular signalling and MB‐inducing effects of MC16 . Mice were used to determine the MB‐inducing effects of MC16 in vivo, and the metabolic effects of MC16 on the renal cortical metabolome. Mouse models of AKI and diabetic kidney disease (DKD) were used to demonstrate the therapeutic potential of MC16 to ameliorate acute and diabetic nephropathy. Key Results MC16 activated the PI3K‐AKT‐eNOS‐FOXO1 axis and induced MB in RPTCs. MC16 induced MB and altered the renal cortical metabolome of mice. MC16 accelerated renal recovery, reduced vascular permeability, and diminished mitochondrial dysfunction following AKI. MC16 decreased diabetes‐induced renal swelling, improved renal and mitochondrial function, and diminished interstitial fibrosis in DKD mouse models. Conclusion and Implications MC16 is a novel compound that induces MB and ameliorates acute and diabetic nephropathy in mice. This study underscores that targeting MB following the onset of renal/metabolic insults may provide a therapeutic strategy to mitigate the onset and/or progression of KD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Organelle BiogenesisDiabetic NephropathiesAcute Kidney InjuryMitochondriaOxindolesAnimalsMiceMice, Inbred C57BLMaleRabbitsCells, CulturedKidney Tubules, Proximal

Stichwörter der Autor:innen

drug discoveryfibrosiskidney diseasemitochondriarenal metabolomics

Substanzen

Oxindoles

Autor:innen und Institutionen

  • Department of Pharmacology and Toxicology, College of Pharmacy, University of Arizona, Tucson, Arizona, USA.
  • U.S. Department of Veterans Affairs, Southern Arizona VA Health Care System, Tucson, Arizona, USA.
  • Southwest Environmental Health Science Center, University of Arizona, Tucson, Arizona, USA.
  • MitoChem Therapeutics, Inc., Charleston, South Carolina, USA.
  • Department of Ophthalmology, College of Medicine, Medical University of South Carolina, Charleston, South Carolina, USA.
  • U.S. Department of Veterans Affairs, Ralph H Johnson VA Health Care System, Charleston, South Carolina, USA.

ORCID-Profile: Austin D Thompson, Kevin A Hurtado, Natalie E Scholpa

Förderung

  • U.S. Department of Veterans Affairs
  • NIEHS NIH HHS
  • BLRD VA
  • NIH HHS
  • National Institutes of Health

Zitieren

APA

Thompson, A. D., Hurtado, K. A., Janda, J., Scholpa, N. E., Rohrer, B., & Schnellmann, R. G. (2025). MC16 promotes mitochondrial biogenesis and ameliorates acute and diabetic nephropathy. British Journal of Pharmacology. https://doi.org/10.1111/bph.17440

Vancouver

Thompson AD, Hurtado KA, Janda J, Scholpa NE, Rohrer B, Schnellmann RG. MC16 promotes mitochondrial biogenesis and ameliorates acute and diabetic nephropathy. British Journal of Pharmacology. 2025. doi:10.1111/bph.17440

BibTeX
@article{Thompson2025,
  author = {Thompson, Austin D and Hurtado, Kevin A and Janda, Jaroslav and Scholpa, Natalie E and Rohrer, Baerbel and Schnellmann, Rick G},
  title = {MC16 promotes mitochondrial biogenesis and ameliorates acute and diabetic nephropathy},
  journal = {British Journal of Pharmacology},
  year = {2025},
  doi = {10.1111/bph.17440}
}
Kostenlos starten →